Liege, Belgium, 21 March 2022 – 17:45 CET – Mithra Pharmaceuticals SA (Euronext Brussels: MITRA)
(the “Company” or “Mithra”), a company dedicated to Women’s Health, today announces that it has exercised a second drawing request for an amount of EUR 5 million, according to the terms of the equity funding agreement signed with Goldman Sachs International (“GSI”) on February 4, 2022.
Further to Mithra’s first drawing requestexercised on 4 February 2022, GSI has elected to exercise a call option for an amount of EUR 5 million. This call option will result in the issuance of 377,198 shares of the Company.
In accordance with article 15 of the Belgian Act of 2 May 2007 on the disclosure of major participations in issuers of which shares are admitted to trading on a regulated market and regarding miscellaneous provisions, following this capital increase’s completion Mithra now has 44,870,648 outstanding shares carrying voting rights (against 44,493,450 outstanding shares carrying voting rights previously).